Kiniksa Pharmaceuticals (NASDAQ:KNSA) Stock Price Down 5.4% on Insider Selling

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) fell 5.4% during mid-day trading on Thursday after an insider sold shares in the company. The stock traded as low as $28.44 and last traded at $28.60. 434,756 shares traded hands during trading, a decline of 14% from the average session volume of 508,421 shares. The stock had previously closed at $30.22.

Specifically, COO Eben Tessari sold 45,042 shares of the business's stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $30.51, for a total value of $1,374,231.42. Following the sale, the chief operating officer now owns 72,363 shares of the company's stock, valued at $2,207,795.13. The trade was a 38.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Eben Tessari sold 10,319 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $30.38, for a total transaction of $313,491.22. Following the completion of the transaction, the chief operating officer now owns 72,363 shares of the company's stock, valued at $2,198,387.94. This represents a 12.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 15,506 shares of the business's stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $30.46, for a total transaction of $472,312.76. Following the sale, the chief operating officer now owns 72,363 shares of the company's stock, valued at $2,204,176.98. The trade was a 17.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Analysts Set New Price Targets

A number of equities analysts have recently commented on KNSA shares. Citigroup initiated coverage on Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They issued a "buy" rating and a $40.00 price target for the company. Jefferies Financial Group raised their target price on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Wall Street Zen lowered Kiniksa Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, June 6th. Finally, Wedbush restated an "outperform" rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, April 16th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Kiniksa Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $38.80.

Kiniksa Pharmaceuticals Price Performance

The stock has a market cap of $2.07 billion, a P/E ratio of -202.13 and a beta of 0.06. The company has a 50 day simple moving average of $24.95 and a 200-day simple moving average of $22.13.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last released its earnings results on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.02 by $0.09. The company had revenue of $137.79 million for the quarter, compared to analyst estimates of $128.35 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The firm's quarterly revenue was up 72.5% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.25) EPS. As a group, research analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Institutional Trading of Kiniksa Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of KNSA. Nuveen Asset Management LLC increased its holdings in Kiniksa Pharmaceuticals by 7.3% during the 4th quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock valued at $15,737,000 after purchasing an additional 54,361 shares during the period. Wellington Management Group LLP grew its stake in shares of Kiniksa Pharmaceuticals by 46.3% in the 4th quarter. Wellington Management Group LLP now owns 69,813 shares of the company's stock worth $1,381,000 after buying an additional 22,096 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Kiniksa Pharmaceuticals by 36.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 122,019 shares of the company's stock valued at $2,414,000 after acquiring an additional 32,393 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Kiniksa Pharmaceuticals during the 4th quarter valued at about $3,955,000. Finally, Globeflex Capital L P increased its position in shares of Kiniksa Pharmaceuticals by 217.1% during the fourth quarter. Globeflex Capital L P now owns 88,596 shares of the company's stock valued at $1,752,000 after acquiring an additional 60,656 shares in the last quarter. Institutional investors own 53.95% of the company's stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.